Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

23 citing papers in PubMed, 38 citations in OpenAlex.

1. A 12-week prospective randomized controlled comparative trial of vilazodone and sertraline in Indian patients with depression.Indian journal of pharmacology
   Trial
2. Serotonin-dopamine interactions in psychostimulant-induced gene regulation: SSRI antidepressants potentiate gene regulation by methylphenidate (Ritalin) in the striatum and enhance behavioral profile indicative of addiction liability in rodents.Neuroscience and biobehavioral reviews · 2025
   Review
3. Safety in treatment: Classical pharmacotherapeutics and new avenues for addressing maternal depression and anxiety during pregnancy.Pharmacological reviews · 2025
   Review
4. Development and validation of a novel fluorometric approach utilizing flow injection analysis for the measurement of vilazodone: application to dosage form and spiked human plasma.BMC chemistry · 2025
   Article
5. Vilazodone, a Novel SSRI Antidepressant with 5-HT1A Partial Agonist Properties: Diminished Potentiation of Chronic Oral Methylphenidate-Induced Dynorphin Expression in the Striatum in Adolescent Male Rats.Molecular neurobiology · 2025
   Article
6. 5-HTBiological psychiatry · 2024
   Article
7. Vilazodone, a Selective Serotonin Reuptake Inhibitor with Diminished Impact on Methylphenidate-Induced Gene Regulation in the Striatum: Role of 5-HT1A Receptor.Molecular neurobiology · 2024
   Article
8. Indole-containing pharmaceuticals: targets, pharmacological activities, and SAR studies.RSC medicinal chemistry · 2024
   Review
9. Role of the Intestinal Microbiota in the Genesis of Major Depression and the Response to Antidepressant Drug Therapy: A Narrative Review.Biomedicines · 2023
   Review
10. Test-Retest Reliability of a Physical Activity Behavior, Health and Wellbeing Questionnaire in Adolescents.Open research Europe · 2023
    Article
11. An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression.Indian journal of psychological medicine · 2023
    Article
12. A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer.Brain, behavior, & immunity - health · 2022
    Review
13. Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice.Neuropsychiatric disease and treatment · 2022
    Review
14. G-protein coupled receptors and synaptic plasticity in sleep deprivation.World journal of psychiatry · 2021
    Review
15. Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson's Disease.Molecules (Basel, Switzerland) · 2021
    Article
16. Piperazine based antimicrobial polymers: a review.RSC advances · 2021
    Review
17. The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease.Cells · 2020
    Article
18. Identification of the Antidepressant Vilazodone as an Inhibitor of Inositol Polyphosphate Multikinase by Structure-Based Drug Repositioning.Molecules and cells · 2020
    Article
19. Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts.Oncotarget · 2017
    Article
20. Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.Bioorganic & medicinal chemistry · 2016
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.